Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
18 September 2015Website:
http://www.penumbrainc.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 23 min agoDividend
Analysts recommendations
Institutional Ownership
PEN Latest News
ALAMEDA, Calif. , Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024.
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Richard Newitter - Truist Securities Robert Marcus - JPMorgan Joanne Wuensch - Citi Michael Sarcone - Jefferies Samantha Kurtz - Piper Sandler Michael Kratky - Leerink Pito Chickering - Deutsche Bank Michael Matson - Needham Operator Good afternoon. My name is Jeremy, and I will be your conference operator today.
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Penumbra (PEN) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.67 per share a year ago.
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.
ALAMEDA, Calif. , Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time.
A researcher initiated coverage of the medical device maker with a confident buy recommendation. He sees multiple positive factors that should propel its growth.
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.
What type of business is Penumbra?
Penumbra, Inc. is a medical company focused on innovative treatment methods, which designs, develops, manufactures, and sells medical devices. The company's products are aimed at two main segments: vascular diseases and neurosurgery. In both of these markets, the company offers key products: thrombectomy systems - for removing blood clots (thrombi) and embolization systems - for treating patients with various sizes of aneurysms and other vascular and nervous disorders. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
What sector is Penumbra in?
Penumbra is in the Healthcare sector
What industry is Penumbra in?
Penumbra is in the Medical Devices industry
What country is Penumbra from?
Penumbra is headquartered in United States
When did Penumbra go public?
Penumbra initial public offering (IPO) was on 18 September 2015
What is Penumbra website?
https://www.penumbrainc.com
Is Penumbra in the S&P 500?
No, Penumbra is not included in the S&P 500 index
Is Penumbra in the NASDAQ 100?
No, Penumbra is not included in the NASDAQ 100 index
Is Penumbra in the Dow Jones?
No, Penumbra is not included in the Dow Jones index
When was Penumbra the previous earnings report?
No data
When does Penumbra earnings report?
The next expected earnings date for Penumbra is 21 February 2025